Monthly Intramuscular Neridronate for the Treatment of Postmenopausal Osteoporosis: Results of a 6-Year Prospective Italian Study
Purpose. Oral bisphosphonates (BPs) are the most commonly used medications for osteoporosis (OP), but their poor gastrointestinal (GI) absorption and tolerance hamper compliance. Intramuscular (IM) neridronate (NE), an amino-BP, is an easy-to-administer, effective, and safe alternative to oral BPs....
Saved in:
Main Authors: | L. Guiducci, C. Vassalle, P. Parchi, S. Maffei |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-01-01
|
Series: | International Journal of Endocrinology |
Online Access: | http://dx.doi.org/10.1155/2019/9802827 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Fracture Incidence, Quality of Life, and Back Pain during 18-Months Treatment with Teriparatide in Greek Postmenopausal Women with Osteoporosis: Results from the European Forsteo Observational Study
by: K. Aloumanis, et al.
Published: (2011-01-01) -
Silicon: A Review of Its Potential Role in the Prevention and Treatment of Postmenopausal Osteoporosis
by: Charles T. Price, et al.
Published: (2013-01-01) -
Regulation of enzymatic lipid peroxidation in osteoblasts protects against postmenopausal osteoporosis
by: Qiong-Yi Zhang, et al.
Published: (2025-01-01) -
The Relationship between Intramuscular Adipose Tissue, Functional Mobility, and Strength in Postmenopausal Women with and without Type 2 Diabetes
by: Janet M. Pritchard, et al.
Published: (2015-01-01) -
The Anti-Inflammatory, Phytoestrogenic, and Antioxidative Role of Labisia pumila in Prevention of Postmenopausal Osteoporosis
by: M. E. Nadia, et al.
Published: (2012-01-01)